These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 16136598

  • 1. Mature T-cell leukemias.
    Ravandi F, Kantarjian H, Jones D, Dearden C, Keating M, O'Brien S.
    Cancer; 2005 Nov 01; 104(9):1808-18. PubMed ID: 16136598
    [Abstract] [Full Text] [Related]

  • 2. The role of alemtuzumab in the management of T-cell malignancies.
    Dearden C.
    Semin Oncol; 2006 Apr 01; 33(2 Suppl 5):S44-52. PubMed ID: 16720203
    [Abstract] [Full Text] [Related]

  • 3. Conjunctival involvement with T-cell prolymphocytic leukemia: report of a case and review of the literature.
    Lee SS, Robinson MR, Morris JC, Mirtsching BC, Shen D, Chan CC.
    Surv Ophthalmol; 2004 Apr 01; 49(5):525-36. PubMed ID: 15325197
    [Abstract] [Full Text] [Related]

  • 4. [Treatment of T-cell prolymphocytic leukemia with monoclonal anti- CD52 antibody (alemtuzumab].
    Fløisand Y, Brinch L, Gedde-Dahl T, Tjønnfjord GE.
    Tidsskr Nor Laegeforen; 2004 Mar 18; 124(6):768-70. PubMed ID: 15039804
    [Abstract] [Full Text] [Related]

  • 5. Mature T-cell leukemias including T-prolymphocytic leukemia, adult T-cell leukemia/lymphoma, and Sézary syndrome.
    Foucar K.
    Am J Clin Pathol; 2007 Apr 18; 127(4):496-510. PubMed ID: 17369126
    [Abstract] [Full Text] [Related]

  • 6. Current treatment options in prolymphocytic leukemia.
    Robak T, Robak P.
    Med Sci Monit; 2007 Apr 18; 13(4):RA69-80. PubMed ID: 17392661
    [Abstract] [Full Text] [Related]

  • 7. Alemtuzumab in peripheral T-cell malignancies.
    Dearden C.
    Cancer Biother Radiopharm; 2004 Aug 18; 19(4):391-8. PubMed ID: 15453953
    [Abstract] [Full Text] [Related]

  • 8. T-cell prolymphocytic leukemia.
    Dearden CE.
    Clin Lymphoma Myeloma; 2009 Aug 18; 9 Suppl 3():S239-43. PubMed ID: 19778847
    [Abstract] [Full Text] [Related]

  • 9. Receptor-directed therapy of T-cell leukemias and lymphomas.
    Morris JC, Waldmann TA, Janik JE.
    J Immunotoxicol; 2008 Apr 18; 5(2):235-48. PubMed ID: 18569395
    [Abstract] [Full Text] [Related]

  • 10. Complete response to alemtuzumab in a patient with B prolymphocytic leukemia.
    Chaar BT, Petruska PJ.
    Am J Hematol; 2007 May 18; 82(5):417. PubMed ID: 17160995
    [No Abstract] [Full Text] [Related]

  • 11. Efficacy of alemtuzumab treatment for refractory T-cell large granular lymphocytic leukemia.
    Rosenblum MD, LaBelle JL, Chang CC, Margolis DA, Schauer DW, Vesole DH.
    Blood; 2004 Mar 01; 103(5):1969-71. PubMed ID: 14976065
    [No Abstract] [Full Text] [Related]

  • 12. CD52 expression in T-cell large granular lymphocyte leukemia--implications for treatment with alemtuzumab.
    Osuji N, Del Giudice I, Matutes E, Morilla A, Owusu-Ankomah K, Morilla R, Dunlop A, Catovksy D.
    Leuk Lymphoma; 2005 May 01; 46(5):723-7. PubMed ID: 16019510
    [Abstract] [Full Text] [Related]

  • 13. T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years.
    Aribi A, Huh Y, Keating M, O'brien S, Ferrajoli A, Faderl S, Wierda W, Kantarjian H, Ravandi F.
    Leuk Res; 2007 Jul 01; 31(7):939-45. PubMed ID: 17045649
    [Abstract] [Full Text] [Related]

  • 14. Alemtuzumab in CLL and other lymphoid neoplasms.
    Ravandi F, O'brien S.
    Cancer Invest; 2006 Nov 01; 24(7):718-25. PubMed ID: 17118783
    [Abstract] [Full Text] [Related]

  • 15. Alemtuzumab.
    Ravandi F, O'Brien S.
    Expert Rev Anticancer Ther; 2005 Feb 01; 5(1):39-51. PubMed ID: 15757437
    [Abstract] [Full Text] [Related]

  • 16. Rapid elimination of circulating leukemia cells with a small dose of alemtuzumab in refractory aggressive NK-cell leukemia.
    Sasaki M, Sugimoto K, Kawahara S, Yasuda H, Suto H, Oshimi K.
    Eur J Haematol; 2007 Jun 01; 78(6):545. PubMed ID: 17419749
    [No Abstract] [Full Text] [Related]

  • 17. Cryptococcal immune reconstitution inflammatory syndrome following alemtuzumab therapy.
    Ingram PR, Howman R, Leahy MF, Dyer JR.
    Clin Infect Dis; 2007 Jun 15; 44(12):e115-7. PubMed ID: 17516390
    [Abstract] [Full Text] [Related]

  • 18. Phase II study of alemtuzumab in chronic lymphoproliferative disorders.
    Ferrajoli A, O'Brien SM, Cortes JE, Giles FJ, Thomas DA, Faderl S, Kurzrock R, Lerner S, Kontoyiannis DP, Keating MJ.
    Cancer; 2003 Aug 15; 98(4):773-8. PubMed ID: 12910522
    [Abstract] [Full Text] [Related]

  • 19. Immunophenotypic characterization of T-cell prolymphocytic leukemia.
    Chen X, Cherian S.
    Am J Clin Pathol; 2013 Nov 15; 140(5):727-35. PubMed ID: 24124154
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.